Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur Acquires 26,448 Shares

Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur acquired 26,448 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was bought at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the acquisition, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Organon & Co. Trading Down 0.4%

Shares of NYSE OGN traded down $0.06 during midday trading on Thursday, hitting $13.36. 3,102,525 shares of the company traded hands, compared to its average volume of 8,179,798. The stock has a 50-day moving average price of $7.90 and a 200 day moving average price of $7.79. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.23 and a current ratio of 1.97. The firm has a market cap of $3.51 billion, a P/E ratio of 14.36, a P/E/G ratio of 1.24 and a beta of 1.57. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.44.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the business earned $1.02 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. As a group, analysts expect that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be issued a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is presently 8.60%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Barclays lifted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Finally, BNP Paribas Exane restated a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Four research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Organon & Co. presently has an average rating of “Reduce” and a consensus target price of $11.40.

Institutional Trading of Organon & Co.

Several large investors have recently added to or reduced their stakes in the business. SEB Asset Management AB bought a new stake in shares of Organon & Co. during the 1st quarter valued at $210,000. Sanctuary Advisors LLC grew its holdings in Organon & Co. by 46.2% during the first quarter. Sanctuary Advisors LLC now owns 42,405 shares of the company’s stock valued at $254,000 after purchasing an additional 13,403 shares during the period. Principal Financial Group Inc. increased its position in Organon & Co. by 2.1% in the first quarter. Principal Financial Group Inc. now owns 1,260,689 shares of the company’s stock worth $7,552,000 after buying an additional 25,495 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of Organon & Co. by 35.9% in the first quarter. 180 Wealth Advisors LLC now owns 227,971 shares of the company’s stock worth $1,366,000 after buying an additional 60,213 shares during the period. Finally, Citizens Financial Group Inc. RI bought a new position in shares of Organon & Co. during the 1st quarter valued at approximately $331,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.